Efficacy and safety of selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors in FGFR-altered urothelial carcinoma
Fibroblast growth factor receptor (FGFR) alteration is one of the common driver alterations in urothelial carcinoma (UC). FGFR alterations contribute to anti-tumor immunity inhibition and are associated with attenuated response to immune checkpoint inhibitor (ICI) or chemotherapy. Selective pan-FGFR...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Pharmacological Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1043661824004882 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553843666550784 |
|---|---|
| author | Yuxuan Song Yiqing Du Shan Jiang Yun Peng Xing Luo Tao Xu |
| author_facet | Yuxuan Song Yiqing Du Shan Jiang Yun Peng Xing Luo Tao Xu |
| author_sort | Yuxuan Song |
| collection | DOAJ |
| description | Fibroblast growth factor receptor (FGFR) alteration is one of the common driver alterations in urothelial carcinoma (UC). FGFR alterations contribute to anti-tumor immunity inhibition and are associated with attenuated response to immune checkpoint inhibitor (ICI) or chemotherapy. Selective pan-FGFR tyrosine kinase inhibitor (FGFRi) has been approved for FGFR-altered UC. However, the comparative efficacy and safety of FGFRi with ICI or chemotherapy remains under debate. We analyzed 865 UC patients including 447 with FGFRi and 418 with ICI or chemotherapy. FGFRi showed better recurrence-free survival for non-muscle invasive UC and higher objective response for advanced UC than ICI or chemotherapy. However, FGFRi demonstrated no benefit for the survival of advanced UC and led to more treatment-related adverse events, especially adverse events causing dose interruptions. It is worth noting that patients with liver metastasis might benefit from FGFRi in terms of both prognosis and response. In summary, FGFRi offered higher efficacy and lower safety in second-line treatment of FGFR-altered UC. It is crucial for clinicians to balance the efficacy and safety in different tumor stages when considering the use of FGFRi for UC treatment. |
| format | Article |
| id | doaj-art-b5a85a6a632f4f9fb13410085212125a |
| institution | Kabale University |
| issn | 1096-1186 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Pharmacological Research |
| spelling | doaj-art-b5a85a6a632f4f9fb13410085212125a2025-01-09T06:13:02ZengElsevierPharmacological Research1096-11862025-01-01211107543Efficacy and safety of selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors in FGFR-altered urothelial carcinomaYuxuan Song0Yiqing Du1Shan Jiang2Yun Peng3Xing Luo4Tao Xu5Department of Urology, Peking University People's Hospital, Beijing 100044, ChinaDepartment of Urology, Peking University People's Hospital, Beijing 100044, ChinaDepartment of Urology, Peking University People's Hospital, Beijing 100044, ChinaDepartment of Urology, Peking University People's Hospital, Beijing 100044, ChinaDepartment of Urology, Peking University People's Hospital, Beijing 100044, ChinaCorresponding author.; Department of Urology, Peking University People's Hospital, Beijing 100044, ChinaFibroblast growth factor receptor (FGFR) alteration is one of the common driver alterations in urothelial carcinoma (UC). FGFR alterations contribute to anti-tumor immunity inhibition and are associated with attenuated response to immune checkpoint inhibitor (ICI) or chemotherapy. Selective pan-FGFR tyrosine kinase inhibitor (FGFRi) has been approved for FGFR-altered UC. However, the comparative efficacy and safety of FGFRi with ICI or chemotherapy remains under debate. We analyzed 865 UC patients including 447 with FGFRi and 418 with ICI or chemotherapy. FGFRi showed better recurrence-free survival for non-muscle invasive UC and higher objective response for advanced UC than ICI or chemotherapy. However, FGFRi demonstrated no benefit for the survival of advanced UC and led to more treatment-related adverse events, especially adverse events causing dose interruptions. It is worth noting that patients with liver metastasis might benefit from FGFRi in terms of both prognosis and response. In summary, FGFRi offered higher efficacy and lower safety in second-line treatment of FGFR-altered UC. It is crucial for clinicians to balance the efficacy and safety in different tumor stages when considering the use of FGFRi for UC treatment.http://www.sciencedirect.com/science/article/pii/S1043661824004882Urothelial carcinomaTargeted cancer therapyFibroblast growth factor receptorImmune checkpoint inhibitor |
| spellingShingle | Yuxuan Song Yiqing Du Shan Jiang Yun Peng Xing Luo Tao Xu Efficacy and safety of selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors in FGFR-altered urothelial carcinoma Pharmacological Research Urothelial carcinoma Targeted cancer therapy Fibroblast growth factor receptor Immune checkpoint inhibitor |
| title | Efficacy and safety of selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors in FGFR-altered urothelial carcinoma |
| title_full | Efficacy and safety of selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors in FGFR-altered urothelial carcinoma |
| title_fullStr | Efficacy and safety of selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors in FGFR-altered urothelial carcinoma |
| title_full_unstemmed | Efficacy and safety of selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors in FGFR-altered urothelial carcinoma |
| title_short | Efficacy and safety of selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors in FGFR-altered urothelial carcinoma |
| title_sort | efficacy and safety of selective pan fibroblast growth factor receptor fgfr tyrosine kinase inhibitors in fgfr altered urothelial carcinoma |
| topic | Urothelial carcinoma Targeted cancer therapy Fibroblast growth factor receptor Immune checkpoint inhibitor |
| url | http://www.sciencedirect.com/science/article/pii/S1043661824004882 |
| work_keys_str_mv | AT yuxuansong efficacyandsafetyofselectivepanfibroblastgrowthfactorreceptorfgfrtyrosinekinaseinhibitorsinfgfralteredurothelialcarcinoma AT yiqingdu efficacyandsafetyofselectivepanfibroblastgrowthfactorreceptorfgfrtyrosinekinaseinhibitorsinfgfralteredurothelialcarcinoma AT shanjiang efficacyandsafetyofselectivepanfibroblastgrowthfactorreceptorfgfrtyrosinekinaseinhibitorsinfgfralteredurothelialcarcinoma AT yunpeng efficacyandsafetyofselectivepanfibroblastgrowthfactorreceptorfgfrtyrosinekinaseinhibitorsinfgfralteredurothelialcarcinoma AT xingluo efficacyandsafetyofselectivepanfibroblastgrowthfactorreceptorfgfrtyrosinekinaseinhibitorsinfgfralteredurothelialcarcinoma AT taoxu efficacyandsafetyofselectivepanfibroblastgrowthfactorreceptorfgfrtyrosinekinaseinhibitorsinfgfralteredurothelialcarcinoma |